AM
AMRN.US Amarin Corporation PLC
- Market cap
- USD 478M
- P/E
- -
- P/B
- 1.10x
- ROE
- -5.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AMRN.US undervalued?
Graham numberThe Graham number of Amarin Corporation PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Amarin Corporation PLC fundamental analysis
No fundamental analysis for Amarin Corporation PLC yet.
Amarin Corporation PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesa…
Full company profileAmarin Corporation PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Amarin Corporation PLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 130M | 181M | 229M | 430M | 614M | 583M | 369M | 307M | 229M | 214M | 169M |
| Gross Profit | 95.7M | 136M | 175M | 334M | 483M | 462M | 242M | 166M | 81.4M | 121M | 65.3M |
| Operating Income | -65.6M | -45.6M | -108M | -24.3M | -19.7M | 10.5M | -106M | -56.6M | -91.8M | -13.9M | -29.8M |
| EBITDA | -56.5M | -44.3M | -107M | -15.0M | -12.7M | 14.3M | -101M | -50.7M | -74.3M | -33.0M | -23.7M |
| Net Income | -86.4M | -67.9M | -116M | -22.6M | -18.0M | 7.73M | -106M | -59.1M | -82.2M | -38.8M | -23.9M |
| EPS | -8.15 | -5.01 | -7.84 | -1.32 | -0.94 | 0.38 | -5.27 | -2.90 | -4.00 | -1.87 | -1.15 |
| Balance Sheet | |||||||||||
| Total Assets | 167M | 162M | 386M | 882M | 966M | 1.07B | 886M | 832M | 685M | 671M | 634M |
| Total Liabilities | 176M | 227M | 233M | 274M | 339M | 401M | 291M | 280M | 199M | 211M | 190M |
| Shareholders' Equity | -9.06M | -65.1M | 152M | 608M | 628M | 667M | 595M | 552M | 486M | 459M | 444M |
| Cash & Short-term Investments | 98.3M | 73.6M | 249M | 645M | 501M | 454M | 309M | 321M | 294M | 303M | 323M |
| Total Debt | 116M | 123M | 80.3M | 59.6M | 9.15M | 8.58M | 10.0M | 8.74M | 7.72M | 12.2M | 7.61M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -71.8M | -32.8M | -94.7M | -9.37M | -21.7M | -66.5M | -180M | 6.91M | -31.0M | 6.74M | 74.5M |
| Capital Expenditure | 21.0K | 12.0K | 58.0K | 2.48M | 252K | 2.41 | 1.89 | 24.1K | 2.00 | 0.00 | 14.67 |
| Free Cash Flow | -71.8M | -32.8M | -94.8M | -11.8M | -22.0M | -66.5M | -180M | 6.88M | -31.0M | 6.74M | 74.5M |
| Ratios | |||||||||||
| ROE | - | - | -76.4% | -3.7% | -2.9% | 1.2% | -17.8% | -10.7% | -16.9% | -8.4% | -5.4% |
| ROA | -51.7% | -42.0% | -30.2% | -2.6% | -1.9% | 0.7% | -11.9% | -7.1% | -12.0% | -5.8% | -3.8% |
| Net Profit Margin | -66.4% | -37.5% | -50.8% | -5.3% | -2.9% | 1.3% | -28.7% | -19.3% | -35.9% | -18.2% | -14.1% |
| Debt to Equity | - | - | 0.53x | 0.10x | 0.01x | 0.01x | 0.02x | 0.02x | 0.02x | 0.03x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Amarin Corporation PLC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 7.17M | 0.38 | - |
| 2019 | USD 2.17M | 0.13 | - |
| 2018 | USD 26.4M | 1.78 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Apr 11, 2025.
Who owns Amarin Corporation PLC
- Insiders 37.19%
- Institutions 20.84%
- Public & others 41.98%
- Shares outstanding 42.0M
- Free float 19.4M
Top funds holding AMRN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Old Westbury Small & Mid Cap Strategies | 58.1K | 0.14% | +4.25% | Jul 2026 |
| SEI International Equity F (SIT) | 20.0K | 0.05% | +46.78% | Oct 2026 |
| State Street® SPDR® Ptf Dev Wld exUS ETF | 17.2K | 0.04% | 0.00% | Oct 2026 |
| Steward Values Enhanced International I | 11.2K | 0.03% | +57.58% | Sep 2026 |
| Voya Multi-Manager International Sm Cp A | 10.5K | 0.03% | 0.00% | Jun 2026 |
| Fidelity Nasdaq Composite Index | 10.1K | 0.02% | -14.43% | Aug 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 9.60K | 0.02% | 0.00% | Oct 2026 |
| Nomura Healthcare Fund Class I | 9.50K | 0.02% | 0.00% | Sep 2026 |
| Acadian European SmCp Eq C2-i-0.7500-EUR | 5.14K | 0.01% | 0.00% | Jun 2026 |
| Hector SICAV FIDE Growth | 3.25K | 0.01% | 0.00% | Jun 2026 |
| First American Multi-Manager IntlEqInstl | 1.90K | 0.00% | 0.00% | Sep 2026 |
Top institutions holding AMRN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sarissa Capital Management LP | 1.67M | 7.92% | 0.00% | Jun 2026 |
| Acadian Asset Management LLC | 721K | 3.41% | +13.23% | Jun 2026 |
| Kynam Capital Management, LP | 533K | 2.52% | +12.83% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 224K | 1.06% | -23.73% | Jun 2026 |
| Waterfront Wealth Inc. | 214K | 1.01% | +5.22% | Jun 2026 |
| Brooklands Fund Management Limited | 177K | 0.84% | +1,036.99% | Jun 2026 |
| Eversept Partners, LP | 145K | 0.69% | -1.64% | Jun 2026 |
| Millennium Management LLC | 116K | 0.55% | -61.47% | Jun 2026 |
| Two Sigma Investments LLC | 101K | 0.48% | -6.54% | Jun 2026 |
| Citadel Advisors Llc | 95.4K | 0.45% | +18.35% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 71.8K | 0.34% | -4.89% | Jun 2026 |
| LCM Capital Management, Inc | 51.4K | 0.24% | +18.18% | Jun 2026 |
| Renaissance Technologies Corp | 48.4K | 0.23% | +151.19% | Jun 2026 |
| Jane Street Group LLC | 37.6K | 0.18% | 0.00% | Jun 2026 |
| George Kaiser Family Foundation | 37.2K | 0.18% | 0.00% | Jun 2026 |
| SEI Investments Co | 29.2K | 0.14% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 29.0K | 0.14% | -23.01% | Jun 2026 |
| Arete Wealth Advisors, LLC | 26.9K | 0.13% | 0.00% | Jun 2026 |
| State Street Corp | 25.0K | 0.12% | +0.27% | Jun 2026 |
| Bleakley Financial Group LLC | 23.5K | 0.11% | -0.25% | Jun 2026 |
Amarin Corporation PLC company profile
- Company name
- Amarin Corporation PLC
- Ticker
- AMRN.US
- Exchange
- USA Stocks
- Listed since
- Apr 1, 1993
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 80
- Fiscal year end
- December
- Address
- One Central Plaza, Dublin, Ireland, D02 K7K5
- Phone
- 353 0 166 99020
- Website
- amarincorp.com
About Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Amarin Corporation PLC management
6- Mr. Aaron D. BergCEO, President & Director · born 1963
- Mr. Peter L. FishmanSenior VP & CFO · born 1984
- Dr. David Keenan Ph.D.Executive VP & Chief Operating Officer · born 1968
- Dr. Steven B. Ketchum Ph.D.Executive VP, President of Research & Development and Chief Scientific Officer · born 1965
- Mr. Jonathan N. ProvoostExecutive VP, Chief Legal & Compliance Officer and Secretary · born 1970
- Mr. Eric BootheSenior Vice President of Corporate Development